Gösterilen 1 - 2 sonuçlar arası kayıtlar. 2, Sorgu süresi: 0.11s Sonuçları Daraltın
  1. 1
    Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

    Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial Yazar: Kerr, R, Love, S, Segelov, E, Johnstone, E, Falcon, B, Hewett, P, Weaver, A, Church, D, Scudder, C, Pearson, S, Julier, P, Pezzella, F, Tomlinson, I, Domingo, E, Kerr, D

    Baskı/Yayın Bilgisi 2016
    Journal article
  2. 2
    Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

    Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial Yazar: Love, S, Kerr, R, Segelov, E, Johnstone, E, Falcon, B, Hewett, P, Weaver, A, Church, D, Scudder, C, Pearson, S, Julier, P, Pezzella, F, Tomlinson, I, Domingo, E, Kerr, D

    Baskı/Yayın Bilgisi 2016
    Journal article

Arama Araçları: